Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,214 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Volunteers Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4302814 in Healthy Participants

NCT07566338
View directory record Official record
Conditions
Healthy
Interventions
LY4302814, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-In-Human Study of LY3839840 in Healthy Participants

NCT06153355
View directory record Official record
Conditions
Healthy
Interventions
LY3839840, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Anaheim, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

NCT00453687
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 12, 2026, 12:58 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

NCT07734649
View directory record Official record
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 12, 2026, 12:58 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers

NCT07843693
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Upadacitinib, Tofacitinib, Baricitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

NCT04052360
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cenerimod, Matching Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

NCT01454986
View directory record Official record
Conditions
Healthy
Interventions
ALXN1007, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects

NCT02327273
View directory record Official record
Conditions
Healthy
Interventions
BMS-963272, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 12, 2026, 12:58 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

NCT00870441
View directory record Official record
Conditions
Safety of ASP2151
Interventions
ASP2151, Valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 12, 2026, 12:58 AM EDT
Terminated Phase 1 Interventional

Sildenafil to Treat HIV-Associated Pulmonary Hypertension

NCT00327080
View directory record Official record
Conditions
HIV
Interventions
MRI, L-NMMA, Acetylcholine
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers

NCT00431951
View directory record Official record
Conditions
Healthy
Interventions
ST-246, Placebo
Drug
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 12, 2026, 12:58 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 12, 2026, 12:58 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

NCT04909723
View directory record Official record
Conditions
Healthy Volunteers, Enteric Hyperoxaluria
Interventions
NOV-001, NB1000S, NB2000P, Placebo
Combination Product · Biological · Drug
Lead sponsor
Novome Biotechnologies Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 12, 2026, 12:58 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

NCT07235059
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
OJR520, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety of FXR-450 in Healthy Subjects

NCT00499629
View directory record Official record
Conditions
Healthy
Interventions
FXR 450, placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional

HIV-1 Vaccine Test in Uninfected Adult Volunteers

NCT00047931
View directory record Official record
Conditions
HIV Seronegativity, AIDS Vaccines
Interventions
VRC-HIVDNA009-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

NCT01074372
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN727, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

NCT03385369
View directory record Official record
Conditions
Safety, Healthy Subjects
Interventions
MEDI0382, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

NCT06877702
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986460
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

NCT02215941
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 12, 2026, 12:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 12, 2026, 12:58 AM EDT